Skip to main content
. 2023 Jun 23;10:1181720. doi: 10.3389/fcvm.2023.1181720

Figure 2.

Figure 2

Timeline of LDL-C levels variations according to lipid-lowering therapy. T1: February 2021 (no lipid-lowering therapy); T2: August 2021 (6-month therapy with high-intensity statin plus ezetimibe); T3: September 2021 (1-month therapy with the addition of PCSK9-inhibitor mAb); T4: February 2022 (3-month PCSK9-inhibitor mAb withdrawal); T5: January 2023 (3-month therapy with the addition of inclisiran).